Intellia Therapeutics Inc (NASDAQ: NTLA) kicked off on Thursday, up 5.39% from the previous trading day, before settling in for the closing price of $6.86. Over the past 52 weeks, NTLA has traded in a range of $5.90-$28.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 15.68% over the past five years. While this was happening, its average annual earnings per share was recorded 10.69%. With a float of $97.42 million, this company’s outstanding shares have now reached $102.03 million.
Let’s look at the performance matrix of the company that is accounted for 403 employees. In terms of profitability, gross margin is 91.17%, operating margin of -923.1%, and the pretax margin is -896.77%.
Intellia Therapeutics Inc (NTLA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Intellia Therapeutics Inc is 5.89%, while institutional ownership is 90.13%. The most recent insider transaction that took place on Mar 04 ’25, was worth 6,104. In this transaction EVP, Chief Technical Officer of this company sold 679 shares at a rate of $8.99, taking the stock ownership to the 95,369 shares. Before that another transaction happened on Mar 04 ’25, when Company’s EVP, General Counsel sold 2,572 for $8.99, making the entire transaction worth $23,122. This insider now owns 111,925 shares in total.
Intellia Therapeutics Inc (NTLA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.52% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Take a look at Intellia Therapeutics Inc’s (NTLA) current performance indicators. Last quarter, stock had a quick ratio of 5.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.25, a number that is poised to hit -1.28 in the next quarter and is forecasted to reach -4.43 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Intellia Therapeutics Inc (NASDAQ: NTLA) saw its 5-day average volume 2.58 million, a negative change from its year-to-date volume of 3.4 million. As of the previous 9 days, the stock’s Stochastic %D was 67.20%. Additionally, its Average True Range was 0.72.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 13.16%, which indicates a significant decrease from 68.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 110.12% in the past 14 days, which was higher than the 80.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.04, while its 200-day Moving Average is $15.74. Nevertheless, the first resistance level for the watch stands at $7.42 in the near term. At $7.60, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.91. If the price goes on to break the first support level at $6.92, it is likely to go to the next support level at $6.61. Assuming the price breaks the second support level, the third support level stands at $6.43.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
The company with the Market Capitalisation of 748.43 million has total of 103,517K Shares Outstanding. Its annual sales at the moment are 57,880 K in contrast with the sum of -519,020 K annual income. Company’s last quarter sales were recorded 12,870 K and last quarter income was -128,900 K.
